logo

Affimed N.V. (AFMD)



Trade AFMD now with
  Date
  Headline
7/1/2021 6:37:37 AM Affimed Q1 Net Income EUR 1.4 Mln Or EUR 0.01/Shr Vs Loss Of EUR 8.3 Mln Or EUR 0.11/Shr Last Year
3/10/2021 6:37:04 AM Affimed To Continue Enrollment In REDIRECT Trial For Patients With Relapsed Or Refractory CD30-positive PTCL
1/13/2021 6:27:42 AM Affimed Prices $100 Mln Public Offering Of Common Shares
12/7/2020 10:11:48 AM Affimed Says AFM13 Monotherapy Was Well Tolerated And Reached An Objective Response Rate
10/6/2020 6:34:57 AM Affimed Doses First Patient In Phase 1 Clinical Trial Of Cord Blood-derived Natural Killer Cells With AFM13
8/11/2020 6:41:56 AM Affimed Q2 Net Loss EUR 12.2 Mln Or EUR 0.16 Per Share
8/5/2020 6:43:39 AM Affimed Appoints Annalisa Jenkins And Harry Welten To Its Supervisory Board
6/23/2020 6:46:45 AM Affimed Q1 Net Loss EUR 8.3 Mln Or EUR 0.11/Shr Vs Income Of EUR 1.9 Mln Or EUR 0.03/Shr Last Year
6/22/2020 9:27:04 AM Affimed Presents Data From Two Investigational ICE Developed From Fit-for-purpose ROCK Platform
6/17/2020 6:52:11 AM Affimed Announces Completion Of First Dose Cohort In Phase 1/2a Clinical Trial Of AFM24
6/11/2020 6:35:00 AM Affimed Appoints Angus Smith As CFO
4/2/2020 6:37:00 AM Affimed Provides COVID-19-Related Business Update
3/17/2020 7:50:34 AM Affimed Names Arndt Schottelius Chief Scientific Officer
1/10/2020 6:34:09 AM Affimed N.V. Appoints Andreas Harstrick As Chief Medical Officer, Starting In March 2020